Bristol Myers Squibb Presented Phase III Cancer Results
New study data for Zenbexus shows improved response rates in patients with relapsed or refractory multiple myeloma.
Updated on Sept. 25, 2026 in Cancer
Live Poll
Do you trust that new medical breakthroughs are meaningfully improving treatment outcomes for patients?
Bristol Myers Squibb released Phase III trial results for its drug Zenbexus, which was tested for the treatment of relapsed or refractory multiple myeloma. The findings were shared with the medical community at the International Myeloma Society annual meeting.
Why it matters
These results provide new clinical insights into treatment options for patients battling multiple myeloma who have not responded to standard therapies. The data offers a potential pathway for improving outcomes in complex cancer cases.
The EXCALIBER-RRMM study tested Zenbexus in combination with daratumumab and dexamethasone. Researchers found that this combination doubled minimal residual disease-negative complete response rates compared to the control regimen.
The players
Bristol Myers Squibb
This global biopharmaceutical company is dedicated to discovering and developing innovative medicines to help patients prevail over serious diseases.
International Myeloma Society
The society is an international organization of scientists and clinicians focused on advancing research and education regarding multiple myeloma.
The details
The trial compared the effectiveness of the Zenbexus combination against a control group treated with daratumumab, bortezomib, and dexamethasone. Published findings in The Lancet Oncology detail how this experimental regimen performed in treating relapsed or refractory multiple myeloma.
Timeline
September 25, 2026: Trial results were presented and published.
The Big Picture
The International Myeloma Society annual meeting serves as a central global venue for disseminating major breakthroughs in blood cancer research. The presentation of the EXCALIBER-RRMM data follows the established pattern of major industry clinical trials being unveiled at this annual scientific gathering.
This development suggests a potential shift in treatment protocols for patients facing relapsed or refractory multiple myeloma. Patients should consult with their oncologists to understand how these findings might influence future care plans.
The takeaway
Clinical advancements in combination therapies remain a critical focus for improving responses in difficult-to-treat cancers. Patients and caregivers should remain updated on new data to discuss potential treatment modifications with their medical teams.
Further reading
For more on the latest research developments, explore the Cancer section.
Live Poll
Do you trust that new medical breakthroughs are meaningfully improving treatment outcomes for patients?
